secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-02-16T23:59:59+00:00
Accession:  0001193125-24-038522
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista prices $160.1M public offering of common stock and pre-funded warrants
-------------------------------------------------------------------------------

- Offering includes 7,016,312 shares at $15.25 and pre-funded warrants for 3,483,688 shares; gross proceeds $160.1M.
- Net proceeds estimated at ~$150.1M to fund sebetralstat development and oral Factor XIIa program.
- Cash, cash equivalents and marketable securities approximately $76M as of Jan 31, 2024 (preliminary).
- Underwriters granted 30-day option to purchase up to 1,575,000 additional shares at same price.
- Closing expected Feb 20, 2024; Jefferies, Leerink, Stifel, Cantor joint book-runners.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/0001193125-24-038522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000119312524038522/d729040d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-038522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer